Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence

References

• U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and HealthThe Health Consequences of Smoking – 50 Years of Progress: A Report of the Surgeon GeneralAtlanta, GAU.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health2014
   Google Scholar
• JhaPPetoRGlobal effects of smoking, of quitting, and of taxing tobaccoN Engl J Med20143701606824382066
   PubMed Web of Science ®Google Scholar
• GohlkeHIs it worth offering cardiovascular disease prevention to the elderly?Eur J Prev Cardiol201320112112622089892
   PubMed Web of Science ®Google Scholar
• Cavazos-RehgPABreslauNHatsukamiDSmoking cessation is associated with lower rates of mood/anxiety and alcohol use disordersPsychol Med201444122523253525055171
   PubMed Web of Science ®Google Scholar
• DollRPetoRBorehamJSutherlandIMortality in relation to smoking: 50 years’ observations on male British doctorsBMJ20043287455151915213107
   PubMed Web of Science ®Google Scholar
• KenfieldSAStampferMJRosnerBAColditzGASmoking and smoking cessation in relation to mortality in womenJAMA2008299172037204718460664
   PubMed Web of Science ®Google Scholar
• NagrebetskyABrettellRRobertsNFarmerASmoking cessation in adults with diabetes: a systematic review and meta-analysis of data from randomised controlled trialsBMJ Open201443e004107
   PubMed Web of Science ®Google Scholar
• ThomsenTVillebroNMollerAMInterventions for preoperative smoking cessationCochrane Database Syst Rev20143CD00229424671929
   PubMed Web of Science ®Google Scholar
• FioreMTreating Tobacco Use and Dependence: 2008 Update: Clinical Practice GuidelineCollingdaleDIANE Publishing2008
   Google Scholar
• SteadLFLancasterTBehavioural interventions as adjuncts to pharmacotherapy for smoking cessationCochrane Database Syst Rev201212CD00967023235680
   PubMed Web of Science ®Google Scholar
• SteadLFLancasterTCombined pharmacotherapy and behavioural interventions for smoking cessationCochrane Database Syst Rev201210CD00828623076944
   PubMed Web of Science ®Google Scholar
• CahillKStevensSPereraRLancasterTPharmacological interventions for smoking cessation: an overview and network meta-analysisCochrane Database Syst Rev20135CD00932923728690
   PubMed Web of Science ®Google Scholar
• SteadLFPereraRBullenCNicotine replacement therapy for smoking cessationCochrane Database Syst Rev201211CD00014623152200
   PubMed Web of Science ®Google Scholar
• KimYKornfieldRShiYEffects of televised direct-to-consumer advertising for varenicline on prescription dispensing in the United States, 2006–2009Nicotine Tob Res Epub2015918
   Web of Science ®Google Scholar
• HaysJTEbbertJOAdverse effects and tolerability of medications for the treatment of tobacco use and dependenceDrugs201070182357237221142259
   PubMed Web of Science ®Google Scholar
• ArnericSPHolladayMWilliamsMNeuronal nicotinic receptors: a perspective on two decades of drug discovery researchBiochem Pharmacol20077481092110117662959
   PubMed Web of Science ®Google Scholar
• SubramaniyanMDaniJADopaminergic and cholinergic learning mechanisms in nicotine addictionAnn N Y Acad Sci20151349466326301866
   PubMed Web of Science ®Google Scholar
• TapperARMcKinneySLNashmiRNicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitizationScience200430656981029103215528443
   PubMed Web of Science ®Google Scholar
• BenowitzNLNicotine addictionN Engl J Med2010362242295230320554984
   PubMed Web of Science ®Google Scholar
• EtterJFCytisine for smoking cessation: a literature review and a meta-analysisArch Intern Med2006166151553155916908787
   PubMedGoogle Scholar
• CoeJWVetelinoMGBashoreCGIn pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (−)-cytisineBioorg Med Chem Lett200515122974297915908213
   PubMed Web of Science ®Google Scholar
• HajekPMcRobbieHMyersKEfficacy of cytisine in helping smokers quit: systematic review and meta-analysisThorax201368111037104223404838
   PubMed Web of Science ®Google Scholar
• CahillKSteadLFLancasterTNicotine receptor partial agonists for smoking cessationCochrane Database Syst Rev20124CD00610322513936
   PubMed Web of Science ®Google Scholar
• MihalakKBCarrollFILuetjeCWVarenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptorsMol Pharmacol200670380180516766716
   PubMed Web of Science ®Google Scholar
• CoeJWBrooksPRVetelinoMGVarenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessationJ Med Chem200548103474347715887955
   PubMed Web of Science ®Google Scholar
• CohenCBergisOEGalliFSSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessationJ Pharmacol Exp Ther2003306140742012682217
   PubMed Web of Science ®Google Scholar
• RollemaHCoeJWChambersLKHurstRSStahlSMWilliamsKERationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessationTrends Pharmacol Sci200728731632517573127
   PubMed Web of Science ®Google Scholar
• FaesselHMSmithBJGibbsMAGobeyJSClarkDJBursteinAHSingle-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokersJ Clin Pharmacol200646999199816920893
   PubMed Web of Science ®Google Scholar
• ObachRSReed-HagenAEKruegerSSMetabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitroDrug Metab Dispos200634112113016221753
   PubMed Web of Science ®Google Scholar
• NiauraRHaysJTJorenbyDEThe efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trialCurr Med Res Opin20082471931194118513462
   PubMed Web of Science ®Google Scholar
• NidesMOnckenCGonzalesDSmoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-upArch Intern Med2006166151561156816908788
   PubMed Web of Science ®Google Scholar
• OnckenCGonzalesDNidesMEfficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessationArch Intern Med2006166151571157716908789
   PubMed Web of Science ®Google Scholar
• JorenbyDEHaysJTRigottiNAEfficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trialJAMA20062961566316820547
   PubMed Web of Science ®Google Scholar
• GonzalesDRennardSINidesMVarenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trialJAMA20062961475516820546
   PubMed Web of Science ®Google Scholar
• TonstadSTonnesenPHajekPWilliamsKEBillingCBReevesKREffect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trialJAMA20062961647116820548
   PubMed Web of Science ®Google Scholar
• TonstadSDaviesSFlammerMRussCHughesJPsychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysisDrug Saf201033428930120297861
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationFDA drug safety communication: safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events Available from: http://www.fda.gov/Drugs/DrugSafety/ucm276737.htmAccessed August 2015
   Google Scholar
• MeyerTETaylorLGXieSNeuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health SystemAddiction2013108120321022812921
   PubMed Web of Science ®Google Scholar
• GibbonsRDMannJJVarenicline, smoking cessation, and neuropsychiatric adverse eventsAm J Psychiatry2013170121460146724030388
   PubMed Web of Science ®Google Scholar
• ThomasKHMartinRMKnipeDWHigginsJPGunnellDRisk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysisBMJ2015350h110925767129
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationFDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of cardiovascular adverse events Available from: http://www.fda.gov/Drugs/DrugSafety/ucm330367.htmAccessed August 2015
   Google Scholar
• SinghSLokeYKSpanglerJGFurbergCDRisk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysisCMAJ2011183121359136621727225
   PubMed Web of Science ®Google Scholar
• HaysJTVarenicline for smoking cessation: is it a heartbreaker?CMAJ2011183121346134721727229
   PubMed Web of Science ®Google Scholar
• ProchaskaJJHiltonJFRisk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysisBMJ2012344e285622563098
   PubMed Web of Science ®Google Scholar
• MillsEJThorlundKEapenSWuPProchaskaJJCardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysisCirculation20141291284124323793
   PubMed Web of Science ®Google Scholar
• PachasGNCatherCPrattSAVarenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week, open-label trialJ Dual Diagn20128211712522888309
   PubMed Web of Science ®Google Scholar
• EvinsAECatherCPrattSAMaintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trialJAMA2014311214515424399553
   PubMed Web of Science ®Google Scholar
• KoegelenbergCFNoorFBatemanEDEfficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trialJAMA2014312215516125005652
   PubMed Web of Science ®Google Scholar
• RamonJMMorchonSBaenaAMasuet-AumatellCCombining varenicline and nicotine patches: a randomized controlled trial study in smoking cessationBMC Med20141217225296623
   PubMed Web of Science ®Google Scholar
• EbbertJOHatsukamiDKCroghanITCombination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trialJAMA2014311215516324399554
   PubMed Web of Science ®Google Scholar
• EbbertJOHughesJRWestRJEffect of varenicline on smoking cessation through smoking reduction: a randomized clinical trialJAMA2015313768769425688780
   PubMed Web of Science ®Google Scholar
• CatzSLJackLMMcClureJBAdherence to varenicline in the COMPASS smoking cessation intervention trialNicotine Tob Res201113536136821350041
   PubMed Web of Science ®Google Scholar
• SuehsBTDavisCGalaznikAJoshiAVZouKHPatelNCAssociation of out-of-pocket pharmacy costs with adherence to vareniclineJ Manag Care Spec Pharm201420659260024856597
   PubMed Web of Science ®Google Scholar
• LibermanJNLichtenfeldMJGalaznikAAdherence to varenicline and associated smoking cessation in a community-based patient settingJ Manag Care Pharm201319212513123461428
   PubMed Web of Science ®Google Scholar
• HollandsGJMcDermottMSLindson-HawleyNVogtFFarleyAAveyardPInterventions to increase adherence to medications for tobacco dependenceCochrane Database Syst Rev20152CD00916425914910
   PubMed Web of Science ®Google Scholar
• NollenNLCoxLSNazirNA pilot clinical trial of varenicline for smoking cessation in black smokersNicotine Tob Res201113986887321498427
   PubMed Web of Science ®Google Scholar